PHASE I STUDY OF A DNA-BASED VACCINE TARGETING PROSTATIC ACID PHOSPHATASE

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这将是一项剂量递增研究，旨在确定DNA疫苗系列皮内接种的安全性，并确定D 0期前列腺癌患者是否可以通过编码PAP的质粒DNA疫苗免疫产生PAP特异性T细胞。这将是一项剂量递增研究，剂量水平将通过质粒DNA疫苗设计，

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be a dose escalation study designed to determine the safety of serial intradermal vaccinations of a DNA-based vaccine and to determine if PAP-specific T cells can be generated in patients with stage D0 prostate cancer by means of immunization with a plasmid DNA vaccine encoding PAP. This will be a dose escalation study and dose levels will be designed by plasmid DNA vaccine d